EBR Systems, Inc. · ASX:EBR
EBR Systems — Shareholder Meeting (May 2022)
9 slides from EBR Systems's shareholder meeting presentation, May 12, 2022
Slide 1: ASX Announcement: 2022 Annual Meeting of Stockholders
ASX ANNOUNCEMENT 12 May 2022 For personal use only 2022 Annual Meeting of Stockholders President & CEO’s Presentation Sunnyvale, California; 12 May 2022: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), is pleased to provide the President & CEO’s presentation to be delivered at the C
Slide 2: Forward-Looking Statements and Foreign Ownership Restriction
enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made.
Slide 3: AGM Presentation May 2022
For personal use only AGM Presentation May 2022
Slide 4: Year in Review
Year in Review For personal use only November 2021 • Raised $110m in an IPO • Listed on the Australian Stock Exchange • Appointed Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler to the Board of Directors • EBR announces appointment of Mr Steve Sandweg as CCO, Mr Michael Hendricksen as COO
Slide 5: Paving the way for expanded indications
Paving the way for expanded indications WiSE ®’s success in additional applications potentially expands EBR’s market opportunity For personal use only ü In 1Q 2022, world’s first and only totally leadless Professor Pascal Defaye said: LBBAP1 implant of Micra® and WiSE® was conducted “I am extremely
Slide 6: Multiple value catalysts
Multiple value catalysts EBR continues to generate value by executing on its clear and targeted commercialisation strategy For personal use only Further growth opportunities Near term value Milestones catalysts q FDA approval in the US achieved q Commercial launch in the US with an initial focus on
Slide 7: Attractive investment opportunity
Attractive investment opportunity For personal use only Unique novel Large addressable De-risked clinical Rapid path to Value upside technology market profile commercialisation potential EBR’s WiSE® is the Targeting initial Currently in final stage of WiSE® has been WiSE® can be extended world’s sma
Slide 8: Disclaimer
Disclaimer The material contained in this document is a presentation of general information about may differ materially from what is expressed in this presentation. For personal use only the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the d
Slide 9: Contact Us
For personal use only Contact Us Company John McCutcheon President & CEO P: +1 408 720 1906 E: [email protected] Investors Nina Lo Vesparum Capital P: +61 3 8582 4800 E: [email protected]